言語を選択

GDF-8

GDF-8 詳細

英語名	Growth/differentiation factor 8	市販薬剤の数	0
治験薬の数	8	ターゲットの別称	MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8
研究＆開発段階	NDA/BLA

英語名	Growth/differentiation factor 8
ターゲットの別称	MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8
市販薬剤の数	0
治験薬の数	8
研究＆開発段階	NDA/BLA

GDF-8 製品リスト

属性
Protein (10)
製品ライブラリ
オンライン (10)
種
Human (5)Human / Mouse / Rat (1)Mouse (2)Cynomolgus (2)
タグ
His Tag (5)Tag Free (1)His Tag & Avi Tag (3)Avi Tag (1)
マーカー
Unconjugated (5)Biotin-labeled (5)

製品番号	種	発現システム	製品説明
HOT GD8-H5243	Human	HEK293	Human latent GDF-8 Protein, His Tag, low endotoxin (pro & latent) (MALS verified)
HOT GD8-H5343	Human	CHO	Human latent GDF-8 Protein, His Tag, low endotoxin (MALS verified)
HOT GD8-H5344	Human / Mouse / Rat	CHO	Human / Mouse / Rat GDF-8 Protein, Tag Free
GD8-H8243	Human	HEK293	Biotinylated Human latent GDF-8 Protein, His Tag, ultra sensitivity (primary amine labeling) (pro & latent) (MALS verified)
GD8-H82Q3	Human	HEK293	Biotinylated Human latent GDF-8 Protein, His,Avitag™ (pro & latent)
GD8-H8313	Human	CHO	Biotinylated Human GDF-8 Protein, Avitag™
GD8-M5243	Mouse	HEK293	Mouse latent GDF-8 Protein, His Tag, low endotoxin
GD8-M82Q3	Mouse	HEK293	Biotinylated Mouse latent GDF-8 Protein, Avitag™,His Tag
GD8-C5243	Cynomolgus	HEK293	Cynomolgus Latent GDF-8 Protein, His Tag, low endotoxin
GD8-C82Q3	Cynomolgus	HEK293	Biotinylated Cynomolgus latent GDF-8 Protein, Avitag™,His Tag

総数量10

GDF-8バックグランド

Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

GDF-8分子の別称

GDF-8, Myostatin, GDF8, MSTN, Growth,differentiation factor 8

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Talditercept alfa	RO-7239361; BMS-986089; RG-6206; BHV-2000	Phase 3 Clinical	Bristol-Myers Squibb Company	Muscular Atrophy, Spinal; Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Obesity; Overweight	詳細
Emugrobart	GYM-329; RG-6237; RG-70240; RO-7204239	Phase 3 Clinical	Chugai Pharmaceutical Co Ltd	Diabetes Mellitus, Type 2; Muscular Atrophy, Spinal; Muscular Dystrophy, Facioscapulohumeral; Obesity; Overweight	詳細
Trevogrumab	REGN-1033; REGN1033; SAR-391786; GDF8	Phase 2 Clinical	Regeneron Pharmaceuticals Inc	Myositis, Inclusion Body; Obesity; Sarcopenia	詳細
AAV1-FS344	AAV1-Follistatin; AAV1-FS344	Phase 2 Clinical	Nationwide Children'S Hospital	Becker muscular dystrophy; Muscular Dystrophy, Duchenne; Myositis, Inclusion Body	詳細
EL-22	EL-22	Phase 1 Clinical		Obesity	詳細
IBIO-600	IBIO-600	Phase 1 Clinical	AstralBio Inc	Obesity; Overweight	詳細
Rinvatercept	RKER-065; KER-065	Phase 1 Clinical	Keros Therapeutics Inc	Neuromuscular Diseases; Obesity	詳細
SRK-439	SRK-439	Phase 1 Clinical	Scholar Rock Inc	Heart Diseases; Obesity	詳細